PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of agdisAging and DiseaseAboutEditorial BoardSubmissionAchieves
 
Aging Dis. Aug 2012; 3(4): 330–338.
Published online Jun 19, 2012.
PMCID: PMC3501368
N-Acetylserotonin and Aging-Associated Cognitive Impairment and Depression
Gregory Oxenkrug* and Rebbie Ratner
Psychiatry and Inflammation Program, Department of Psychiatry, Tufts Medical Center, Tufts University School of Medicine, Boston, MA, 02111, USA
*Correspondence should be addressed to: Gregory F. Oxenkrug, Tufts Medical center, 800 Washington St, #1001, Boston, MA, 02111, USA., Email: goxenkrug/at/tuftsmedicalcenter.org
Received June 5, 2012; Revised June 16, 2012; Accepted June 16, 2012.
Normal brain aging is associated with depression and cognitive decline. One of the mechanisms of aging-associated emotional and cognitive impairment might be the down-regulation of biosynthesis of N-acetylserotonin (NAS), one of the methoxyindole derivatives of tryptophan (TRP). Aging is associated with decreased NAS production, largely resulting from the down-regulation of beta 1 adrenoreceptors that activate serotonin N-acetyltransferase, the enzyme catalyzing formation of NAS from serotonin. NAS exerts antidepressant-like and cognition-enhancing effects. The NAS role in cognition supported by the discovery that scotophobin, decapeptide extracted from brain and associated with cognition improvement, inhibits NAS conversion into melatonin. Furthermore, NAS (and its derivatives) attenuated cognitive impairment induced by cholinergic neurotoxin and protected against beta-amyloid neurotoxicity. Considering that NAS (but not serotonin or melatonin) is a potent agonist to high-affinity BDNF tyrosine kinase (TrkB) receptors, antidepressant and cognition-enhancing effect of NAS might be mediated by activation of TrkB receptors. NAS and TRkB gradually decreased from 1 postnatal week becoming undetectable in the brains of old rats. Additional mechanisms might include non-receptor mediated anti-inflammatory and anti-oxidative effects of NAS. Therapeutic antidepressant and cognition-improving interventions might include administration of NAS and its analogs; inhibition of tryptophan - kynurenine metabolism to increase serotonin availability as a substrate for NAS biosynthesis; up-regulation of NAS formation from serotonin and down-regulation of NAS conversion into melatonin.
Keywords: N-acetylserotonin, aging, memory, scotophobin, BDNF, TrkB
N-acetylserotonin (NAS) was considered only as an intermediate product (and immediate precursor) of melatonin biosynthesis from serotonin. The finding that the memory-enhancing (in the model of dark avoidance) effect of NAS (but not melatonin) and that the brain decapeptide (scotophobin) caused dark avoidance due to inhibition of NAS conversion into melatonin [1] was completely underappreciated [2]. G. Brown and his team were the first to suggest that NAS may have a role in the central nervous system distinct from that of being a precursor for melatonin. This hypothesis was based on the immunohistochemically identified presence of NAS in specific brain areas separate from melatonin and serotonin (e.g., brain stem, cerebellum and hippocampus, and within the reticular formation nuclei and motor nuclei of the brain stem); on the inhibitory action of NAS on glutamate induced firing of pyramidal cells; and on its analgesic effect (separate from melatonin and serotonin) [36]. They wrote “If this hypothesis is correct it would suggest that indoleamines have certain similarities to catecholamines. Thus for the catecholamines, dopamine, norepinephrine and epinephrine form a synthetic sequence and yet have independent roles as neurotransmitters and/or hormones. The three indoleamines serotonin, NAS and melatonin also form a synthetic sequence and these three substances may also have independent roles as neurotransmitters and/or hormones [3].
Our support of the “NAS hypothesis” was based on our observation of NAS effects (cognition-enhancing, antidepressant-like, antihypertensive, prolongation of life span, prevention of pathological opening of the mitochondrial permeability transition pores, protection from beta-amyloid toxicity inhibition of lipid peroxidation) that were independent from melatonin or much stronger than similar effects of melatonin) [710]. Recent discovery that NAS (but not melatonin or serotonin) is an agonist to brain derived neurotropic factor (BDNF), tyrosine kinase (TrkB) receptors [11,12] provides further and crucial support for the hypothesis that NAS has a role in the central nervous system distinct from that of being a precursor for melatonin.
The present paper offers a review of the literature and author’s data on NAS role in aging and aging-associated depression and cognitive impairment.
N-acetylserotonin (NAS) was initially indentified in the urine of rats and rabbits as an additional (to oxidative deamination and re-uptake) pathway of serotonin metabolism [13]. NAS production occurs mostly in the pineal gland and retina [14]. However, NAS was also found in the hypothalamus, cortex, cerebellum, olfactory bulb, spinal cord and peripheral tissues [3,6,15]. Conversion of serotonin (formed from tryptophan) into NAS is catalyzed by serotonin-N-acetyl transferase (SNAT) [16,17]. The next step in NAS metabolism is methylation of NAS into melatonin catalyzed by hydroxyindole-O-methyl transferase (HIOMT) [14]. About 15% of melatonin is converted “back” into NAS in humans [18] and in rats [19] (Fig.1).
Figure 1.
Figure 1.
N-acetylserotonin biosynthesis.
Under physiological conditions, the rate-limiting factors of NAS biosynthesis from serotonin are 1) availability of serotonin as an immediate substrate for NAS biosynthesis, and 2) up-regulation of beta-adrenoceptors that mediate noradrenalin-induced stimulation of SNAT [17]. The circadian rhythm of SNAT is generated within the hypothalamic suprachiasmatic nuclei (SCN), site of the circadian clock. Environmental light signal transmitts from the retina to the pineal gland primarily via the retinohypothalamic tract and superior cervical ganglion (SCG) [20].
Increased sympathetic tone (e.g., in spontaneously hypertensive rats) resulted in higher (than in normotensive rats) elevation of pineal NAS in response to stimulation by increased production of NA-induced by cold immobilization stress or clorgyline [21].
Pinealocyte’s beta-adrenoceptors develop supersensitivity (increase in Bmax) during the light phase of light: dark cycle. With the beginning of dark, NA, released from nerves originating in SCG, stimulates up-regulated beta-receptors, and, consequently, triggers the de novo synthesis of SNAT. Regulation of the circadian rhythm of NAS biosynthesis varies between species, e.g., pineal beta-adrenoceptor density of the Wistar rat did not decline as rats age [22]. Therefore, it was important to evaluate NAS biosynthesis in the human pineal. We studied 24-hour cycle of serotonin, NAS, melatonin, and beta adrenoceptor density in human pineal glands obtained from 77 post-mortem sources from various times of death. Density (Bmax) of pineal beta adrenoceptors (but not receptors affinity that remained in narrow ranges near 58 pM) was relatively constant between midnight and 18.00 h and became significantly higher between 18.00 and 20.00 h as measured by ligand saturation binding experiments using (125-I) iodocyanopindolol. The up-regulation of receptors coincided with an increase in the concentration of serotonin that began to rise between 16.00 and 20.00 h and became maximal between 20.00 and midnight. NAS was at maximal levels between 20.00 h and midnight. Both serotonin and NAS began declining after midnight, and this change corresponded to the maximal pineal gland concentration of melatonin between midnight and 4.00 h. It is therefore suggested that the up-regulation of beta adrenoceptors noted during the late afternoon and early evening hours corresponds to the increased synthesis of serotonin and the subsequent conversion to NAS [23]. Aging-associated reduced density of adrenergic receptors [24] might contribute to aging-associated decline of NAS biosynthesis (see below).
NAS biosynthesis and aging
Ontogenetically, pineal NAS appears earlier than melatonin. Rat pineal SNAT is active while HIOMT is absent during first week of neonatal life. Our in vivo and in vitro studies reveal that clorgyline stimulates pineal NAS biosynthesis from day five onward with a marked increase between day 14 and day 21. In contrast, MEL is not increased until day 21, with a sharp rise thereafter [25].
Aging is associated with the declined content [2629] and flattened circadian rhythm of NAS in normotensive [30] and spontaneously hypertensive rats [7,8]. The expression of pineal and hippocampus SNAT mRNA was lower in old (24 months) than in young (2 months) rats [31].
Aging affects two major rate-limiting factors of NAS biosynthesis: 1) up-regulation of beta-adrenoceptors, and 2) availability of serotonin.
Beta-receptors
Aging is associated with a reduced density of adrenergic receptors and reduced adaptation of these receptors to changing neuronal input, e.g., up-regulation in response to light–induced suppression of NA release [24]. We reported that clorgyline, monoamine oxidase type A (MAO-A) inhibitor, increased NAS content in both 3 and 12 months old male Sprague-Dawley rats kept under regular (12:12 h) light: dark schedule, suggesting the preservation of the enzymatic machinery for NAS biosynthesis in aged rats. However, only young but not middle-aged rats responded by additional elevation of pineal NAS when exposed to light for 24 h before administration of clorgyline, or serotonin precursor, 5-hydroxytryptophan [32,33]. In the same vein, administration of isoproterenol, beta-adrenoceptor agonist, caused lower elevation of pineal NAS content in older than in younger spontaneously hypertensive rats [7,8,10]. These observations suggested that aging-associated reduced density of pineal beta-adrenergic receptors contributed to aging-associated decline of NAS biosynthesis.
Availability of serotonin
Decreased availability of serotonin as a substrate for NAS biosynthesis might the consequence of aging-associated activation of TRP conversion into kynurenine (KYN) that shifts TRP metabolism from serotonin to KYN production [34].
It is noteworthy that genetic or pharmacological inhibition of KYN formation from TRP (that is supposed to increase the availability of serotonin as a substrate for NAS biosynthesis) prolongs life span in Drosophila melanogaster [3537].
Calcification of pineal gland
Aging-associated decline of NAS biosynthesis might be a consequence of calcification of human (but not rat) pineal gland. Human pineal gland, the major site of NAS biosynthesis, undergoes increased calcification during the life cycle [38]. Alzheimer’s disease patients had more severe pineal calcification than age-matched control [39]. Our postmortem study of 33 subjects (age range 3 months to 65 years) calcium deposits (evaluated by atomic absorption spectrometry) revealed a positive correlation with age in both day and night samples (day: r = 0.56, P < 0.05; night: r = 0.818, P < 0.001) [40].
Degeneration of the retina-SCN-pineal axis may underlie disrupted NAS production and rhythms in aging and in the very first preclinical stages of Alzheimer’s Disease. Our studies revealed that chemical [41] or surgical [42] sympathectomy; or lesions of SCN [43] attenuated or abolished NA-induced stimulation of rat pineal NAS biosynthesis.
Aging and jetlag
Circadian rhythms (i.e, nighttime increase of pineal SNAT and NAS) were abolished for three nights after 8 hrs advance of the beginning of the light phase of light: dark cycle (experimental model of jetlag associated with eastward flights) [47,48]. Reappearance of the circadian rhythms of NAS biosynthesis was delayed in aged rats in comparison to the young animals [48].
Pharmacological down-regulation of NAS biosynthesis
The use of beta-blockers and benzodiazepines (BZ) is increased in elderly. Both medications negatively affect cognitive functions and NAS biosynthesis. Our in vivo and in vitro studies revealed that administration of the central BZ agonist, clonazepam, or the mixed agonist-antagonist, diazepam, inhibited nocturnal elevation of SNAT [49].
NAS and life span
NAS administered in drinking water at 2.5 mg/kg/day starting at 4 weeks of age delayed the occurrence of first death from 11 to 15-th month of age, and prolonged the life span of C3H male mice by more than 20% [50]. To the best of our knowledge this was the first report of a prolongation of life span by NAS.
NAS might contribute to life span extension effect of irreversible MAO-B type inhibitor, deprenyl. Night- (but not day-time) pineal NAS levels were increased after six months of subcutaneous administration of deprenyl (0.25 mg/kg) to retired female breeders Fisher 344N rats [51,52].
NAS and “memory peptide”, scotophobin
The idea that memories could be transferred from one organism to another by administration of a “trained” donor brain to a naive recipient seized both scientific and public attention in the 1960’s and early 1970’s [2]. One of the “memory peptide” candidates was identified in the brain extracts of rats trained with shock to avoid dark (hence, “scotophobin”), leading to synthesis of its analogs [53]. Scotophobin induced avoidance behavior and heightened emotionality as measured by defecation rate when mice were locked in the dark box, but not when they were locked in a white or transparent box [54]. Scotophobin was found to be an effective inhibitor (KI50, 6 × 10(−7) M) of purified bovine HIOMT, the enzyme, converting NAS in to melatonin. The finding that scotophobin inhibits HIOMT suggested that NAS is a mediator of the memory-enhancing effect of scotophobin. Further experiments confirmed that scotophobin action required intact pineal, and that NAS induced dark avoidance in goldfish, as did S-adenosyl-homocysteine, another HIOMT inhibitor [1].
Cognition-enhancing and neuroprotective effects of NAS
We found that three weeks of NAS treatment reversed the impairment of performance in active avoidance (learning and retention paradigms) and water maze tests induced in Wistar rats by cholinergic neurotoxin ethylcholine aziridinium (single intracerebroventricular injection of 3 nmol) [55].
NAS and aging-associated oxidative stress
Aging is associated with increased production of reactive oxygen species and oxidation-induced damage to intracellular structures and membranes. We found an age-associated increase of lipid peroxidation (malonaldehyde+4-hydroxyalkenals, MDA+HAE) in the liver (from 3- to 6- to 12-months old), and kidney (from 3- to 6-month without further increase in 12–months old animals) of genetically deficient for NAS formation C57Bl/6j male mice. MDA+4HAE brain levels did not differ between 3-, 6- and 12-months old animals, leaving the possibility that lipid peroxidation has already reached it peak at 3-month of age [56].
We observed that subcutaneous injections of NAS (four weeks, 30 mg/kg/day) decreases brain (2.2 fold) and kidney MDA+HAE in 11-month old male C57BL/6J mice. While control animals had large areas of baldness, NAS-treated animals had the healthy and luxuriant fur, and lost about 10% of their initial body weight in comparison with no weight loss in control group [50].
The cognition enhancing effect of NAS might be further supported by our observations of NAS protective effect against ß-amyloid toxicity in cultured rat cerebellar granulate cells [55] and MPP+ and ß-amyloid–induced pathological activation of mitochondrial permeability transition pores [57].
NAS attenuated lipopolysaccharide-, iron- and TNF-alpha-induced lipid peroxidation [5860]. Other mechanisms of the antioxidant effects of NAS might include stimulation of glutathione peroxidase; suppression of phospholipase A2; and inhibition of sepiapterin reductase, the key enzyme of biosynthesis of tetrahydrobiopterin, the essential cofactor of nitric oxide synthase [9].
NAS and N-methyl-d-aspartate (NMDA)
Aging- and depression-associated up-regulation of TRP – KYN metabolism (see above) lead to increased production of endogenous NMDA receptors antagonist, kynurenic acid (KYNA), one of the KYN derivatives [61] (Fig.2). Exogenous NMDA receptors antagonist, MK-801, inhibits SNAT (and, presumably, NAS biosynthesis) [62]. Therefore, increased production of endogenous KYNA might (similar to exogenous antagonist, MK-801) inhibit NAS biosynthesis and contribute to KYNA-induced cognitive impairment associated with aging and depression ([62]. On the other hand, the inhibitory effect of NAS on glutamate-induced firing of pyramidal cells [4] and glutamate-induced lipid peroxidation in retinal homogenates [63] might contribute to the cognition-enhancing effect NAS.
Figure 2.
Figure 2.
Tryptophan shift from Serotonin to Kynurenine formation.
NAS and neurogenesis
NAS might contribute to its cognition-enhancing and antidepressant effects by promoting hippocampal neuroprogenitor cell proliferation (64) and increasing cell proliferation through upregulation of BDNF [65].
NAS and depression
Aging is associated with the increased prevalence of late onset depression, one of the components of aging-associated medical and psychiatric disorders, including metabolic syndrome [6668]. One of the mechanisms of aging-associated depression might be the shift of TRP metabolism from formation of NAS (and other methoxyindoles, such as serotonin and melatonin) to production of kynurenines (Fig.2) [69,70]. The other consequence of up-regulated TRY – KYN metabolism is the increased formation of neuroactive KYN derivatives, the endogenous NMDA agonists and antagonist [71].
NAS and antidepressant effect
The antidepressant-like effect of NAS was reported in a mice tail-suspension test [72] and confirmed in a forced swim test [11]. Selective tricyclic antidepressants and serotonin uptake inhibitors increased SNAT mRNA expression [73]. Our in vivo and in vitro experiments revealed that acute administration of irreversible (clorgyline) and reversible (brofaromine, beflaxotone, moclobemide) selective monoamine oxidase (MAO) type A inhibitors and high doses (or chronic administration of low doses) of relatively selective MAO-B inhibitors (but not of highly selective MAO-B inhibitors) suppressed MAO-A activity and stimulated pineal NAS biosynthesis. The effect of MAO-A inhibitors is strain (spontaneously hypertensive rats > Fisher344N > Wistar Kyoto > Sprague-Dawley) and gender (male > female) dependent [74,75]. Considering that MAO-A but not MAO-B inhibitors exert a clinically antidepressant effect, our data suggested that stimulation of NAS biosynthesis contributes to the antidepressant effect of MAO-A inhibitors. Antidepressant and selective MAO-A inhibitor, clorgyline, stimulates rat pineal NAS biosynthesis by preserving MAO-A substrates (serotonin and NA) from deamination [76]. Reversible MAO-A inhibitors, brofaromine and beflaxotone, stimulated pineal NAS production as well [8]. We reported that antidepressant, methylene blue, and other blue dyes, the selective MAO-A inhibitors [77] stimulate pineal NAS production [78]. Acute administration of MAO-B type inhibitor, deprenyl (not exerting an antidepressant effect), did not stimulate rat pineal NAS biosynthesis. However, chronic (6 months) injections of low dose of deprenyl, an irreversible MAO-B inhibitor, inhibits MAO-A and stimulated pineal NAS production but only during the dark phase [51,52].
The bioprecursor amino acid (MDL 72394) is converted into the irreversible selective MAO-A inhibitor (MDL 72392) by aromatic L-amino acid decarboxylase (AADC). Pretreatment with carbidopa, peripheral AADC inhibitor, which does not penetrate blood-brain-barrier (BBB), prevents the liberation of the MAO-A inhibitor outside the BBB and results in exclusive inhibition of brain MAO-A. We found that systemic administration of MDL 72394 (0.5 mg/kg) stimulated rat pineal melatonin biosynthesis. Carbidopa, in a dose-dependent manner, attenuated or completely prevented MDL-induced stimulation of melatonin biosynthesis in the pineal gland confirming the location of the pineal gland outside of BBB (although in the brain) [79].
NAS and QR2/MT3
Besides non-receptor mediated anti-oxidant (see above) effects of NAS, some receptors-mediated effects of NAS might contribute to it antidepressant action. The melatonin 3 type (MT-3) receptor has higher affinity to NAS than to melatonin, and was identified as the same protein as quinone reductase 2 (QR2) detoxifying and antioxidant enzyme [80]. We found that QR2/MT3 agonist 5-methoxycarbonylamino-N-acetyltryptamine (5MCA-NAT) decreased, while the QR2/MT3 antagonist prazosin increased the duration of immobility in the tail suspension test in C57BL/6 mice. Prazosin, in a dose that did not affect the duration of immobility, attenuated the antidepressant-like effect of NAS and 5MCA-NAT [81]. It is noteworthy that QR2/MT3 mediated effects appeared to be specific for antidepressant-like action since 5MCA-NAT did not affect NAS-induced protection against LPS toxicity [58].
5MCA-NAT NAS as agonist to TrkB receptors
The most important step in establishing NAS biological activity independent from serotonin and melatonin is a recent discovery that NAS (but not serotonin or melatonin) is an agonist to tyrosine kinase B(TrkB) (but not TrkA or TrkC) receptors of brain derived neurotrophic factor (BDNF) [11]. Recent review indicates that activation of TrkB by NAS might contribute to cognition-enhancing, neuroprotective and antidepressant effects of NAS (and MAO-A inhibitors) [12]. Discovery of the TrkB-mediated antidepressant effect of NAS is in line with the hypothesis that loss of BDNF is directly involved in the pathophysiology of depression, and that its restoration may underlie the therapeutic efficacy of antidepressant treatment [82]. NAS-induced TrkB stimulation might be especially important for the treatment of age-associated depression and cognitive decline considering the age-associated decrease in expression of BDNF (mRNAs and proteins) and its neuronal and glial (TrkB) receptors [83].
Current review strongly suggests that NAS has an important role in mechanisms of aging-associated depression and impairment of cognition. NAS and its derivative might serve as new tools in prevention and treatment of aging-associated emotional and cognitive decline; and for protection against oxidative stress- and inflammation-related conditions (cell death, mutagenesis, aging) and diseases (sepsis, cancer, postischemic trauma, Alzheimer’s disease, Parkinsonism and retinal degeneration). Therapeutic antidepressant and cognition-improving interventions might include administration of NAS and its analogs; inhibition of tryptophan-kynurenine metabolism to increase serotonin availability as a substrate for NAS biosynthesis; up-regulation of NAS formation from serotonin and down-regulation of NAS conversion into melatonin.
Acknowledgments
This review is dedicated to the memory of dear friend and colleague, Prof Arthur Yuwiler (1927 –2012).
[1] Satake N, Morton BE. Scotophobin A causes dark avoidance in goldfish by elevating pineal N-acetylserotonin. Pharmacol Biochem Behav. 1979;10:449–456. [PubMed]
[2] Setlow B. Georges Ungar and memory transfer. J Hist Neurosci. 1997;6:181–92. [PubMed]
[3] Brown GM, Pulido O, Grota LJ, Niles LP. N-Acetylserotonin in the central nervous system. Prog Neuropsychopharmacol Biol Psychiatry. 1984;8:475–80. [PubMed]
[4] Bubenik GA, Brown GM, Grota LG. Differential localization of N-acetylated indolealkylamines in CNS and the Harderian gland using immunohistology. Brain Res. 1976;118:417–427. [PubMed]
[5] Psarakis S, Brown GM, Grota LJ. Analgesia induced by N-acetylserotonin in the central nervous system. Life Sci. 1988;42:1109–1116. [PubMed]
[6] Pulido O, Brown GM, Grota LJ. B-adrenergic regulation of N-acetylserotonin (NAS) synthesis in the rat cerebellum. Life Sci. 1983;33:1081–9. [PubMed]
[7] Oxenkrug GF. N-acetylserotonin and the hypotensive effect of MAO-A inhibition (mini-review) Vopr. Med. Khim. 1998;43:522–526. (Russian). [PubMed]
[8] Oxenkrug GF. Antidepressive and antihypertensive effects of MAO-A inhibition: role of N-acetylserotonin (a review) Neurobiology. 1999;7:213–224. [PubMed]
[9] Oxenkrug GF. Antioxidant effects of N-acetylserotonin: possible mechanisms and clinical implications. Ann N Y Acad Sci. 2005;1053:334–347. [PubMed]
[10] Oxenkrug GF. Antidepressant effect of N-acetylserotonin in relation to aging, hypertension and cancer. In: Berstein L, editor. Hormones, age and cancer. Nauka; St.Petersburg: 2005. pp. 140–158.
[11] Jang SW, Liu X, Pradoldej S, Tosini G, Chang Q, Iuvone PM, Ye K. N-acetylserotonin activates TrkB receptor in a circadian rhythm. Proc Natl Acad Sci U S A. 2010;107:3876–3881. [PubMed]
[12] Tosini G, Ye K, Iuvone PM. N-Acetylserotonin: Neuroprotection, Neurogenesis, and the Sleepy Brain. 2012 May 14; [Epub ahead of print] [PMC free article] [PubMed]
[13] McIsaac WM, Page IH. The Metabolism of Serotonin (5-Hydroxytryptamine) J Biol Chem. 1959;234:858–864. [PubMed]
[14] Axelrod J. The pineal gland: a neurochemical transducer. Science. 1974;1184:1341–1348. [PubMed]
[15] Raikhlin NT, Kvetnoĭ IM, Kadagidze ZG, Sokolov AV. [Immunohistochemical demonstration of the localization of melatonin and N-acetylserotonin in enterochromaffin cells] Biull Eksp Biol Med. 1976;82:1400–1411. [PubMed]
[16] Weissbach H, Redfield BG, Axelrod J. Biosynthesis of melatonin: enzymic conversion of serotonin to N-acetylserotonin. Biochim Biophys Acta. 1960;43:352–3. [PubMed]
[17] Klein D, Weller JL. Adrenergic-adenosine 3′,5′-monophosphate regulation of serotonin N-acetyltransferase activity and the temporal relationship of serotonin N-acetyltransferase activity synthesis of 3H-N-acetylserotonin and 3H-melatonin in the cultured rat pineal gland. J Pharmacol Exp Ther. 1973;186:516–27. [PubMed]
[18] Young IM, Leone RM, Francis P, Stovell P, Silman RE. Melatonin is metabolized to N-acetyl serotonin and 6-hydroxymelatonin in man. J Clin Endocrinol Metab. 1985;60:114–119. [PubMed]
[19] Leone RM, Silman RE. Melatonin can be differentially metabolized in the rat to produce N-acetylserotonin in addition to 6-hydroxymelatonin. Endocrinology. 1984;114:1825–1832. [PubMed]
[20] Skene DJ, Swaab DF. Melatonin rhythmicity: effect of age and Alzheimer’s disease. Exp Gerontol. 2003;38:199–206. [PubMed]
[21] Oxenkrug GF, Requintina PJ. The effect of MAO-A inhibition and cold-immobilization stress on N-acetylserotonin and melatonin in SHR and WKY rats. J Neural Transm Suppl. 1998;52:333–6. [PubMed]
[22] Dax EM, Sugden D. Age-associated changes in pineal adrenergic receptors and melatonin synthesizing enzymes in the Wistar rat. J Neurochem. 1978;50:468–72. [PubMed]
[23] Oxenkrug GF, Anderson GF, Dragovic L, Blaivas M, Riederer P. Circadian rhythms of human pineal melatonin, related indoles, and beta adrenoreceptors: post-mortem evaluation. J. Pineal Res. 1990;9:1–11. [PubMed]
[24] Weiss B. Modulation of adrenergic receptors during aging. Neurobiol Aging. 1988;9:61–2. [PubMed]
[25] Oxenkrug GF, Requintina PJ, Yuwiler A. Ontogenetic effects of MAO-A inhibition on rat pineal n-acetylserotonin and melatonin during the first month of neonatal life. Hum Psychopharmacol. 2000;15:589–593. [PubMed]
[26] Míguez JM, Recio J, Sánchez-Barceló E, Aldegunde M. Changes with age in daytime and nighttime contents of melatonin, indoleamines, and catecholamines in the pineal gland: a comparative study in rat and Syrian hamster. J Pineal Res. 1998;25:106–15. [PubMed]
[27] Pang SF, Tang F, Tang PL. Negative correlation of age and the levels of pineal melatonin, pineal N-acetylserotonin, and serum melatonin in male rats. J Exp Zool. 1984;229:41–7. [PubMed]
[28] Friedman E, Cooper T, Yocca F. The effect of imipramine treatment on brain serotonin receptors and beta-adrenoceptors and on pineal beta-adrenergic function in adult and aged rats. Eur J Pharmacol. 1986;123:351–6. [PubMed]
[29] Bondarenko LA, Anisimov VN. [Age-related characteristics of the effects of epithalamin on serotonin metabolism in the pineal gland of rats] Biull Eksp Biol Med. 1992;113:194–5. [PubMed]
[30] Pulido O, Clifford J. Age-associated changes in the circadian rhythm of retinal N-acetylserotonin and melatonin in rats with pigmented eyes. Exp Gerontol. 1986;21:23–30. [PubMed]
[31] Uz T, Qu T, Sugaya K, Manev H. Neuronal expression of arylalkylamine N-acetyltransferase (AANAT) mRNA in the rat brain. Neurosci Res. 2002;42:309–16. [PubMed]
[32] McIntyre IM, Oxenkrug GF. Effect of ageing on melatonin synthesis induced by 5-hydroxytryptophan and constant light in rats. Prog Neuropsychopharmacol Biol Psychiatry. 1991;15:561–6. [PubMed]
[33] Oxenkrug GF, McIntyre IM, Requintina PJ, Duffy JD. The response of the pineal melatonin biosynthesis to the selective MAO-A inhibitor, clorgyline, in young and middle-aged rats. Prog Neuropsychopharmacol Biol Psychiatry. 1991;15:895–902. [PubMed]
[34] Oxenkrug GF. Interferon-gamma – Inducible Inflammation: Contribution to Aging and Aging-Associated Psychiatric Disorders. Aging and Disease. 2011;2:474–486. [PMC free article] [PubMed]
[35] Kamyshev MG. Longevity and its relation to the locomotor activity in tryptophan-xanthommatin metabolic pathway mutant of Drosophila. Dokl Acad Nauk USSR. 1980;253:1476–80.
[36] Oxenkrug GF. The extended life span of Drosophila melanogaster eye-color (white and vermilion) mutants with impaired formation of kynurenine. J Neural Transm. 2010;117:23–26. [PMC free article] [PubMed]
[37] Oxenkrug G, Navrotskaya V, Vorobyova L, Summergrad P. Extension of life span of Drosophila melanogaster by the inhibitors of tryptophan – kynurenine metabolism. Fly (Austin) 2011;5:307–309. [PMC free article] [PubMed]
[38] Pillai KM. Pineal gland calcification. Neurol India. 1968;16:35–6. [PubMed]
[39] Mahlberg R, Walther S, Kalus P, Bohner G, Haedel S, Reischies FM, Kühl KP, Hellweg R, Kunz D. Pineal calcification in Alzheimer’s disease: an in vivo study using computed tomography. Neurobiol Aging. 2008;29:203–9. [PubMed]
[40] Schmid HA, Requintina PJ, Sturner WQ, Oxenkrug GF. Calcium, aging and melatonin biosynthesis in human pineals. J Pineal Res. 1997;16:178–183. [PubMed]
[41] Reuss S, Requintina PJ, Riemann R, Oxenkrug GF. Clorgyline effect on pineal melatonin biosynthesis in adrenalectomized rats pretreated with 6-hydroxydopamine. J Neural Transm, Suppl. 1994;41:135–9. [PubMed]
[42] Oxenkrug GF, Requintina PJ. Clorgyline effect on pineal melatonin biosynthesis in rats with lesioned suprachiasmatic nuclei. J Neural Transm Suppl. 1998;52:329–32. [PubMed]
[43] McIntyre IM, McCauley R, Murphy S, Goldman H, Oxenkrug GF. Effect of superior cervical ganglionectomy on melatonin stimulation by specific MAO-A inhibition. Biochem Pharmacol. 1985;34:3393–4. [PubMed]
[44] Oxenkrug GF, Requintina PJ, Yuwiler A. Does moclobemide stimulate melatonin synthesis as the other selective MAO-A inhibitors do? J Neural Transm Suppl. 1990;32:171–5. [PubMed]
[45] Reuss S, Oxenkrug GF. Chemical sympathectomy and clorgyline-induced stimulation of rat pineal melatonin synthesis. J. Neural Transm. 1989;1989;78:167–172. [PubMed]
[47] Illnerová H. Mechanism of the re-entrainment of the circadian rhythm in the rat pineal N-acetyltransferase activity to an eight-hour advance of the light-dark cycle: phase-jump is involved. Brain Res. 1989;494:365–8. [PubMed]
[48] Oxenkrug GF, Requintina PJ. Melatonin and jet lag syndrome: experimental model and clinical implications. CNS Spectrums. 2003;8:139–148. [PubMed]
[49] Winters WD, Yuwiler A, Oxenkrug GF. The effects of benzodiazepines on basal and isoproterenol-stimulated N-acetyltransferase activity by the rat pineal gland, in vivo and in vitro. 1991;10:151–8. [PubMed]
[50] Oxenkrug GF, Requintina PJ, Bachurin S. Antioxidant and anti-aging activity of N-acetylserotonin in the in vivo and in vitro models. Ann New York Acad Sci. 2001;939:190–199. [PubMed]
[51] Oxenkrug GF, Requintina PJ, Correa RM, Yuwiler A. The effect of 6-months l-deprenyl administration on pineal MAO-A and MAO-B activity and on the content of melatonin and related indoles in aged female Fisher 344N rats. J Neural Transm Suppl. 1994;41:249–52. [PubMed]
[52] Oxenkrug GF. Anti-Aging Effect of (-) Deprenyl and Inhibition of Lipid Peroxidation by N-acetylserotonin and Mating (a mini-review) In: Torok T, Klebovich L, editors. Monoamine Oxidase inhibitors and their role in neurotransmission (drug development) Medicina Publishing House Co; Budapest: 2004. pp. 309–319.
[53] Ungar G, Desiderio DM, Parr W. Isolation, identification, and synthesis of a specific-behavior-inducing brain peptide, Nature. 1972;238:198–202. [PubMed]
[54] Malin DH. Synthetic scotophobin: Analysis of behavioral effects on mice. Pharm Biochem Behav. 1974;2:147–153. [PubMed]
[55] Bachurin S, Oxenkrug G, Lermontova N, et al. N-acetylserotonin, melatonin and their derivatives improve cognition and protect against b-amyloid-induced neurotoxicity, Ann. New York Acad Sci. 1999;1999;890:155–166. [PubMed]
[56] Oxenkrug GF, Requintina PJ. Mating attenuates aging-associated increase of lipid peroxidation activity in C57BL/6J mice. Ann N Y Acad Sci. 2003;993:161–7. [PubMed]
[57] Bachurin SO, Shevtsova EP, Oxenkrug GF, Sablin SO. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci. 2003;993:334–344. [PubMed]
[58] Requintina PJ, Oxenkrug GF. Differential effects of lipopolysaccharide on lipid peroxidation in F344N, SHR rats and BALB/C mice and protection of melatonin and NAS against Its toxicity. Ann N Y Acad Sci. 2003;993:325–333. [PubMed]
[59] Perianayagam MC, Oxenkrug GF, Jaber BL. Immune-modulating effects of melatonin, N-acetylserotonin, and N-acetyldopamine. Ann N Y Acad Sci. 2005;1053:386–93. [PubMed]
[60] Oxenkrug GF, Requintina PJ. N-acetyldopamine inhibits rat brain lipid peroxidation induced by lipopolysaccharide and iron. Ann N Y Acad Sci 2005. 2005;1053:394–399. [PubMed]
[61] Alexander KS, Wu HQ, Schwarcz R, Bruno JP. Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine. Psychopharmacology (Berl) 2012;220:627–37. [PubMed]
[62] Zawilska JB, Rosiak J, M. Sendereska M, Nowak LZ. Suppressive effect of NMDA receptor antagonist MK-801 on nocturnal serotonin Nacetyltransferase activity in the rat pineal gland. Pol J Pharmacol. 1997;49:479–483. [PubMed]
[63] Tang GY, Ip AK, Siu AW. Pinoline and N-acetylserotonin reduce glutamate-induced lipid peroxidation in retinal homogenates. Neurosci Lett. 2007;412:191–4. [PubMed]
[64] Sompol P, Liu X, Baba K, Paul KN, Tosini G, Ivone PM, et al. N-acetylserotonin promotes hippocampal neuroprogenitor cell proliferation in sleep-deprived mice. Proc Natl Acad Sci U S A. 2011;108:8844–8849. [PubMed]
[65] Yoo DY, M, Kim W, Lee CH, Won MH, Hwang IK, Yoon YS. N-Acetylserotonin Increases Cell Proliferation and Differentiating Neuroblasts with Tertiary Dendrites through Upregulation of Brain-Derived Neurotrophic Factor in the Mouse Dentate Gyrus. J Vet Med Sci. 2011 Jun 28; [Epub ahead of print] [PubMed]
[66] Dilman VM, Lapin IP, Oxenkrug GF. Serotonin and aging. In: Essman W, editor. Serotonin in health and disease. Vol. 5. Spectrum Press; NY-London: 1979. pp. 111–123.
[67] Oxenkrug GF. Metabolic syndrome, age-associated neuroendocrine disorders, and dysregulation of tryptophan-kynurenine metabolism. Ann N Y Acad Sci. 2010;1199:1–14. [PubMed]
[68] Oxenkrug GF. Interferon-gamma-inducible kynurenines/pteridines inflammation cascade: implications for aging and aging-associated medical and psychiatric disorders. J Neural Transm. 2011;118:75–85. [PMC free article] [PubMed]
[69] Lapin IP, Oxenkrug GF. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet. 1969;1:32–39. [PubMed]
[70] Oxenkrug GF. Tryptophan–kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: Serotonin hypothesis revisited 40 years later. Israel J Psychiatry. 2010;47-1:56–63. [PMC free article] [PubMed]
[71] Oxenkrug GF. Genetic and hormonal regulation of the kynurenine pathway of tryptophan metabolism: new target for clinical intervention in vascular dementia, depression and aging Ann. N Y Acad Sci. 2007;1122:35–49. [PubMed]
[72] Prakhie IV, Oxenkrug GF. The effect of nifedipine, Ca++ antagonist on activity of MAO inhibitors, N-acetylserotonin and melatonin in the mouse tail suspension test. J Neuropsychopharmac. 1998;1:35–40. [PubMed]
[73] Uz T, Manev H. Chronic fluoxetine administration increases the serotonin N-acetyltransferase messenger RNA content in rat hippocampus. Biol Psychiatry. 1999;45:175–9. [PubMed]
[74] Oxenkrug GF, McCauley R, McIntyre IM, Filipowicz C. Selective inhibition of MAO-A but not MAO-B activity increases rat pineal melatonin. J Neural Transm. 1985;61:265–70. [PubMed]
[75] Oxenkrug GF. The acute effect of monoamine oxidase inhibitors on serotonin conversion to melatonin. In: Sandler M, Coppen A, Harnett S, editors. 5-hydroxytryptamine in Psychiatry: A spectrum of Ideas. Oxford New York Tokyo: Oxford University Press; 1991. pp. 98–109.
[76] Oxenkrug GF, McIntyre IM, McCauley R, Yuwiler A. The effect of selective MAO inhibitors on rat pineal melatonin synthesis in vitro. J Pineal Res. 1988;5:99–109. [PubMed]
[77] Sablin S, Ransay RR. Difference spectra for inhibitor binding to monoamine oxidases. Biochem Soc Trans. 1995;23:457S. [PubMed]
[78] Oxenkrug GF, Sablin SO, Requintina PJ. Effect of methylene blue and related redox dyes on monoamine oxidase activity; rat pineal content of N-acetylserotonin, melatonin, and related indoles; and righting reflex in melatonin-primed frogs. Ann N Y Acad Sci. 2007;1122:245–52. [PubMed]
[79] Oxenkrug GF, Requintina PJ, Yuwiler A, Palfreyman MG. The acute effect of the bioprecursor of the selective brain MAO-A inhibitor, MDL 72392, on rat pineal melatonin biosynthesis. J Neural Transm Suppl. 1994;41:377–9. [PubMed]
[80] Boutin JA, Marcheteau E, Hennig P, et al. MT3/QR2 melatonin binding site does not use melatonin as a substrate or a co-substrate. Pineal Res. 2008;45:524–531. [PubMed]
[81] Oxenkrug GF, Bachurin SO, Prakhie IV, Zefirov N. Quinone reductase 2 and antidepressant effect of melatonin derivatives. Ann N Y Acad Sci. 2010;1199:121–124. [PubMed]
[82] Sandler M. Neurotrophins: possible role in anxiety and affective disorders. Hum Psychopharmacol Clin Exp. 2001;16:61–64. [PubMed]
[83] Silhol M, Bonnichon V, Rage F, Tapia-Arancibia L. Age-related changes in brain-derived neurotrophic factor and tyrosine kinase receptor isoforms in the hippocampus and hypothalamus in male rats. Neuroscience. 2005;132:613–24. [PubMed]
Articles from Aging and Disease are provided here courtesy of
JKL International LLC